NASDAQ:VKTX Viking Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.82 -0.07 (-2.42%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$2.72▼$2.9450-Day Range$2.11▼$2.8952-Week Range$2.02▼$7.20Volume49,682 shsAverage Volume1.11 million shsMarket Capitalization$218.19 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Viking Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside378.7% Upside$13.50 Price TargetShort InterestBearish6.68% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment1.23Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.90) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.22 out of 5 starsMedical Sector259th out of 1,427 stocksPharmaceutical Preparations Industry127th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.50, Viking Therapeutics has a forecasted upside of 378.7% from its current price of $2.82.Amount of Analyst CoverageViking Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.68% of the float of Viking Therapeutics has been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Viking Therapeutics has recently decreased by 1.92%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreViking Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Viking Therapeutics is -0.88. Previous Next 3.5 News and Social Media Coverage News SentimentViking Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Viking Therapeutics this week, compared to 0 articles on an average week.Search Interest11 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions46.74% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viking Therapeutics are expected to decrease in the coming year, from ($0.90) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Viking Therapeutics (NASDAQ:VKTX) StockViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Read More VKTX Stock News HeadlinesJune 7, 2022 | finance.yahoo.comIntercept (ICPT) Announces Delay in Meeting With the FDAJune 6, 2022 | finance.yahoo.comOne Viking Therapeutics, Inc. (NASDAQ:VKTX) insider upped their stake by 43% in the previous yearMay 16, 2022 | finance.yahoo.comViking Therapeutics to Present at H.C. Wainwright Global Investment ConferenceApril 28, 2022 | benzinga.comSVB Leerink Maintains Outperform on Viking Therapeutics, Lowers Price Target to $12April 28, 2022 | seekingalpha.comViking Therapeutics' (VKTX) CEO Brian Lian on Q1 2022 Results - Earnings CallApril 27, 2022 | za.investing.comViking Therapeutics Misses Q1 EPS by 2cApril 27, 2022 | seekingalpha.comViking Therapeutics GAAP EPS of -$0.21 misses by $0.02April 27, 2022 | finance.yahoo.comViking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateApril 20, 2022 | seekingalpha.comRevisiting Viking TherapeuticsApril 6, 2022 | finance.yahoo.comViking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferenceMarch 8, 2022 | finance.yahoo.comViking Therapeutics to Present at Upcoming Investor ConferencesFebruary 10, 2022 | seekingalpha.comViking Therapeutics rises 8% following Q4 resultsFebruary 7, 2022 | finance.yahoo.comViking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare ConferenceJanuary 28, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXJanuary 27, 2022 | apnews.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. – VKTXJanuary 26, 2022 | finance.yahoo.comViking (VKTX) Study on X-ALD Put on Clinical Hold by the FDAJanuary 24, 2022 | seekingalpha.comFDA puts clinical hold on Viking Therapeutics' Phase 1b trial of VK0214 in X-ALDJanuary 24, 2022 | nasdaq.comViking Therapeutics Says FDA Places Clinical Hold On Phase 1b Trial Of VK0214 - Quick FactsJanuary 24, 2022 | finance.yahoo.comViking Therapeutics' Early Stage Trial On FDA Hold In Rare Metabolic DisorderDecember 28, 2021 | finance.yahoo.comViking Therapeutics, Inc. (NASDAQ:VKTX) insider upped their holding by 43% earlier this yearDecember 17, 2021 | finance.yahoo.comuniQure (QURE) Falls on Data From Huntington's Disease StudyDecember 6, 2021 | finance.yahoo.comBristol Myers (BMY) sBLA for Reblozyl Gets Priority ReviewDecember 6, 2021 | finance.yahoo.comDown 24.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Viking Therapeutics, Inc. (VKTX)December 3, 2021 | finance.yahoo.comNovartis (NVS) Highlights Growth Profile at its R&D DayNovember 30, 2021 | finance.yahoo.comFennec (FENC) Gets CRL From FDA for Pedmark, Stock DownSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VKTX CUSIPN/A CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees17Year FoundedN/ACompany Calendar Last Earnings4/27/2022Today7/04/2022Next Earnings (Estimated)7/27/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$13.50 High Stock Price Forecast$15.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+378.7%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.77% Return on Assets-26.31% Debt Debt-to-Equity RatioN/A Current Ratio17.16 Quick Ratio17.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book1.09Miscellaneous Outstanding Shares77,374,000Free Float73,118,000Market Cap$218.19 million OptionableOptionable Beta1.45 Viking Therapeutics Frequently Asked Questions Should I buy or sell Viking Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Viking Therapeutics stock. View analyst ratings for Viking Therapeutics or view top-rated stocks. What is Viking Therapeutics' stock price forecast for 2022? 5 Wall Street analysts have issued twelve-month price targets for Viking Therapeutics' stock. Their VKTX stock forecasts range from $10.00 to $15.00. On average, they expect Viking Therapeutics' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 378.7% from the stock's current price. View analysts' price targets for Viking Therapeutics or view top-rated stocks among Wall Street analysts. How has Viking Therapeutics' stock performed in 2022? Viking Therapeutics' stock was trading at $4.60 at the beginning of the year. Since then, VKTX shares have decreased by 38.7% and is now trading at $2.82. View the best growth stocks for 2022 here. When is Viking Therapeutics' next earnings date? Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Viking Therapeutics. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its quarterly earnings results on Wednesday, April, 27th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. During the same period in the previous year, the business posted ($0.19) EPS. View Viking Therapeutics' earnings history. Who are Viking Therapeutics' key executives? Viking Therapeutics' management team includes the following people: Dr. Brian Lian Ph.D., Pres, CEO & Director (Age 56, Pay $872k)Mr. Gregory S. Zante, Chief Financial Officer (Age 51, Pay $536k)Ms. Marianne Mancini, Chief Operating Officer (Age 57, Pay $543k)Mr. Michael Morneau, VP of Fin. & Admin. (Age 57) Who are some of Viking Therapeutics' key competitors? Some companies that are related to Viking Therapeutics include Morphic (MORF), ADVANZ PHARMA (CXRXF), Phibro Animal Health (PAHC), Design Therapeutics (DSGN), IGM Biosciences (IGMS), Nuvation Bio (NUVB), Avidity Biosciences (RNA), CinCor Pharma (CINC), Verve Therapeutics (VERV), Pharvaris (PHVS), Theravance Biopharma (TBPH), Catalyst Pharmaceuticals (CPRX), Erasca (ERAS), PMV Pharmaceuticals (PMVP) and Kiniksa Pharmaceuticals (KNSA). View all of VKTX's competitors. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO). When did Viking Therapeutics IPO? (VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager. What is Viking Therapeutics' stock symbol? Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX." How do I buy shares of Viking Therapeutics? Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Viking Therapeutics' stock price today? One share of VKTX stock can currently be purchased for approximately $2.82. How much money does Viking Therapeutics make? Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $218.19 million. The biotechnology company earns $-54,990,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. How many employees does Viking Therapeutics have? Viking Therapeutics employs 17 workers across the globe. How can I contact Viking Therapeutics? Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for Viking Therapeutics is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com. This page (NASDAQ:VKTX) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here